Stocks Health care ALGS
NASDAQ · Health careAligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. brought in $3.7M of revenue over the twelve months to June 30, 2026, up 19.4% from a year earlier. It posted a net loss of $76M. At June 30, 2026 it held $30.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Aligos Therapeutics, Inc. does
Aligos Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALGS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.2M | -$24.2M | -$2.45 | n/a |
| 2024 | $3.6M | -$131.2M | -$20.94 | -$80.9M |
| 2023 | $6.2M | -$87.7M | -$34.20 | -$79M |
| 2022 | $0 | -$96M | -$56.58 | -$80.3M |
| 2021 | $0 | -$128.3M | -$80.97 | -$116.6M |
| 2020 | $0 | -$108.5M | -$273.35 | -$76.3M |
Latest SEC filings
What Aligos Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 26, 2026
- June 24, 2026Activist stake (5% or more) SCHEDULE 13D
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
Questions about ALGS
What does Aligos Therapeutics, Inc. do?
Aligos Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALGS.
Is Aligos Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $76M on revenue of $3.7M.
How much revenue does Aligos Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Aligos Therapeutics, Inc. reported revenue of $3.7M. That is 19.4% more than a year earlier.
When did Aligos Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 15, 2026.
Similar companies
Follow ALGS
Get an email when Aligos Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ALGS: get an email when it filesWhere the numbers come from
Financial figures are the values Aligos Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.